Content Type: Article

  • Short-Selling — Belgium, France, Italy and Spain Announce Short-Selling Bans

    Short-Selling — Belgium, France, Italy and Spain Announce Short-Selling Bans

    ARTICLE / CLIENT ALERT

    Short-Selling — Belgium, France, Italy and Spain Announce Short-Selling Bans

    March 17, 2020

    Read time: 3 min

    Key takeaways
    Overview

    Four EU member states have announced temporary short-selling bans under the EU Short Selling Regulation (“SSR”) aimed at preventing disorderly trading resulting from the COVID-19 outbreak. Managers should be aware that further restrictive measures under the SSR are likely in the coming days.

    Belgium

    The restriction on short sales and “similar transactions” applies until the end of the trading day on March 17, 2020. The ban covers a list of shares admitted to trading on Euronext Brussels. The full text of the decision is available here.

    France

    The ban applies until the end of trading day on March 17, 2020 and covers a list of 92 shares admitted to trading on Euronext Paris, Euronext Growth Paris and Euronext Access.

    AMF’s decision and the list of covered stocks is available here.

    Italy

    The prohibition on short sales applies for the entire trading day of March 17, 2020 and covers a list of 20 stocks. Consob has also announced that it intends to take further temporary measures under the SSR. These are likely to include a short-selling ban covering a range of transactions and applicable for up to three months (similar to the Spanish ban below).

    The full text of Consob’s decision is available here

    Spain

    The prohibition applies for one month until the end of the trading day on April 17, 2020. The ban may be extended for an additional period not exceeding three months. The ban covers all types of short transactions in the shares admitted to trading on Spanish trading venues, including cash short sales, derivatives and indices (other than indices or baskets where a majority of constituent shares are not covered by the ban).

    Net short positions (including increases to existing net shorts) that (i) result from delta-neutral positions in convertible bonds (where a short position is taken to cover the exposure to the equity component) or (ii) are offset by a purchase of subscription rights are excluded from the ban.

    The full text of the release is available here.

    Authored by Anna Maleva-Otto, Brian T. Daly, Julian Rainero and Craig Stein.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This communication is issued by Schulte Roth & Zabel LLP and Schulte Roth & Zabel International LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP and Schulte Roth & Zabel International LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Craig Stein

    Partner

    New York – 919 Third Avenue

    More insights

  • Employer Concerns — COVID-19

    Employer Concerns — COVID-19

    ARTICLE / CLIENT ALERT

    Employer Concerns — COVID-19

    March 17, 2020

    Read time: 8 min

    Key takeaways
    Overview

    As COVID-19 spreads across the globe, employers must act quickly while continuing to comply with applicable employment laws and the evolving guidance put forth by various government agencies. Below are some of the main issues facing employers and guidance on what employers can and cannot do.

    Potentially Infected Employees

    If an employee exhibits flu-like symptoms while at work, employers are permitted to ask them to seek medical attention. Employers can ask employees to get tested for COVID-19 as long as the employee’s condition could pose a “direct threat” to the workforce, defined as a “significant risk of substantial harm to the health and safety of the individual or others that cannot be eliminated or reduced by reasonable accommodation.” Moreover, according to guidance set forth by the Equal Employment Opportunity Commission (“EEOC”), an employer may require symptomatic employees to go home without violating the Americans with Disabilities Act (“ADA”). If an employee tests positive for COVID-19, employers are expected to send home all employees who were in close contact (within six feet) with that employee for a 14-day self-monitoring period to help prevent the spread of the infection. The employer should then inform other employees in the same work location or facility of this potential exposure to the virus in the workplace.

    Discrimination and Harassment Issues

    Employers should ensure the confidentiality of employee medical information to prevent discrimination and harassment against employees exhibiting symptoms. All practices and policies regarding COVID-19 must be uniformly applied to avoid the risk of employee discrimination claims (i.e., employers should not treat employees differently based on their ethnicity, national origin, disability, age or any other protected class).

    Wage and Hour Issues

    The Fair Labor Standards Act (“FLSA”) generally does not require an employer to pay employees who are not working. Exempt employees (i.e., certain executive, professional and administrative employees who are exempt from the overtime pay requirements), however, must ordinarily be paid their full weekly salary if they work during any portion of the workweek. Employers could also be obligated to keep paying employees because of an underlying employment contract or collective bargaining agreement.

    Remote Work

    The EEOC has advised that telework is an appropriate infection-control strategy. An employer can choose to implement a remote work period to assist in the effort to slow the spread of COVID-19. If employers decide to leverage their remote work capabilities, they should prepare policies concerning the providing and appropriate use of computers and other items necessary to work remotely. One area to focus on is the protection of confidential or sensitive information.

    Employee Leave

    Employers can require that employees take available sick or paid leave for absences related to COVID-19. The CDC advises employers to review current policies and to “ensure that [ ] sick leave policies are flexible and consistent with public guidance and that employees are aware of these policies.” For quarantined employees who cannot perform their jobs remotely, employers may consider an extension of paid leave benefits.

    Employees may be eligible for short-term disability leave if they are diagnosed with COVID-19 and are sick and unable to perform the major duties of their job due to the sickness.

    If an employee’s symptoms rise to a serious medical condition that renders the employee unable to work, that employee may be eligible for unpaid leave under the Family and Medical Leave Act (“FMLA”). Employees caring for a qualifying family member with COVID-19 who meet the criteria under FMLA may also be permitted to take such protected leave. Employees who refuse to come to work due to fear of contracting COVID-19 are likely not eligible for FMLA leave. Similarly, the New York Paid Family Leave Act provides employees with up to 10 weeks of paid leave to care for a family member with a serious health condition. This leave cannot be used for the employee’s own health condition.

    On March 14, 2020, the U.S. House of Representatives passed the Families First Coronavirus Response Act which has the support of President Trump. Assuming this act, or something similar, is passed by the senate, several provisions will affect employers. The act includes three separate provisions relating to employee absences due to COVID-19 — a temporary expansion of the FMLA, including providing for paid FMLA leave, a new federal paid sick leave law and expanded unemployment insurance benefits.

    Health Plan Design

    Sponsors of health plans can amend their plans to provide new eligibility rules and/or benefits in response to the COVID-19 outbreak. For example, the IRS recently issued guidance permitting high deductible health plans (“HDHPs”) to provide benefits associated with the testing and treatment of COVID-19 without a deductible or with a deductible that is lower than the one that would normally apply under the plan.

    Plan sponsors may also elect to amend their plans to waive copays and co-insurance for COVID-19 testing. In New York, for example, insurance carriers for fully-insured health plans must waive cost sharing for COVID-19 testing as well any emergency room, urgent care and office visits associated therewith. Because this is a state insurance mandate, self-insured plans are not required to do so.

    Plan sponsors should also review their plans’ eligibility terms to make sure the rules are not unintentionally exclusionary. For example, plan sponsors may wish to consider amending their eligibility rules to ensure employees continue to have access to their health plan coverage throughout any potential quarantine time. In addition, plan sponsors should ensure that any new class of individual they may hire (e.g., temporary employees) to fill work-related gaps during the COVID-19 outbreak are receiving the appropriate coverage required under the terms of the plan and applicable law.

    Finally, plan sponsors should ensure that plan documents, including summary plan descriptions and summaries of benefits and coverage, are easily accessible to all participants who may be working remotely.

    HIPAA Privacy Considerations

    The Office for Civil Rights at the U.S. Department of Health and Human Services issued a bulletin to remind covered entities and business associates of their obligations with respect to individuals’ protected health information (“PHI”) under HIPAA’s Privacy Rule (“Privacy Rule”). The bulletin outlines the limited circumstances when PHI may be disclosed under the Privacy Rule during the COVID-19 outbreak.

    Under the Privacy Rule, covered entities and business associates may disclose PHI, without a person’s individual HIPAA authorization, in limited circumstances including:

    • As necessary to treat the patient or a different patient;
    • To a public health authority, such as the CDC or a state health department, that is legally authorized to collect such information;
    • To an affected individual’s family members, relatives, friends or other people identified by the individual as involved in his or her care; and
    • To lessen or prevent a serious or imminent threat to the health and safety of a person or the general public.

    Even if a disclosure of PHI is permitted under HIPAA, a covered entity or business associate must take reasonable steps to ensure that the information disclosed is limited to the minimum amount necessary to accomplish the purpose of the disclosure. Disclosures to the media or the general public about a specific individual with COVID-19 or his or her test results or treatment are generally prohibited without the individual’s written authorization. Different rules apply if the individual is incapacitated or unconscious and cannot give his or her authorization. While HIPAA does not apply to many employers, because they are not covered entities or business associates, maintaining confidentiality of employee health information is also required under the ADA and various state privacy protection laws.

    OSHA and Workplace Safety Issues

    Under the Occupational Safety and Health Act (“OSHA”), employers have a general duty to provide a safe and healthy workplace for their employees. OSHA recently published guidance (https://www.osha.gov/Publications/OSHA3990.pdf) which outlines some of the steps employers can take to help maintain a healthy work environment, protect their workforce and comply with the law. The OSHA guidance recommends that employers develop an infectious disease preparedness and response plan, if one is not already in place. OSHA further advises that employers implement basic infection prevention measures.

    COVID-19 is an unprecedented situation and guidance is being issued and evolving daily. Employers should continue to monitor all CDC and other government communications on a daily basis and should keep in touch with their workforce through regular communications.

    Authored by Mark E. Brossman, Ronald E. Richman, Donna K. Lazarus, Scott A. Gold, Melissa J. Sandak and Max Garfield.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Mark E. Brossman

    Partner

    New York – 919 Third Avenue

    Ronald E. Richman

    Partner

    New York – 919 Third Avenue

    Donna K. Lazarus

    Partner

    New York – 919 Third Avenue

    Max Garfield

    Partner

    New York – 919 Third Avenue

    More insights

  • Real Estate Deals and Leases — COVID-19 Considerations

    Real Estate Deals and Leases — COVID-19 Considerations

    ARTICLE / CLIENT ALERT

    Real Estate Deals and Leases — COVID-19 Considerations

    March 17, 2020

    Read time: 7 min

    Key takeaways
    Overview

    The continuing spread of COVID-19 across the United States has compelled businesses to grapple with weakened financial markets, legal restrictions hindering the mobility of people and goods and disruption to daily workplace operations stemming from, among other things, compliance with CDC guidelines.

    While we are closely monitoring the impact of COVID-19 on the U.S. commercial real estate market and the business operations of our clients, we are also advising clients on numerous legal issues that directly impact ongoing transaction negotiations. This Alert focuses on contractual provisions in existing documents that should be examined in light of concerns raised by the COVID-19 outbreak. As parties negotiate and litigate these provisions, future provisions will become more tailored to address considerations presented by COVID-19.

    Parties to purchase and sale agreements, lease agreements and loan documents should strongly consider how they are affected by COVID-19 and its adverse impacts. Many contracts contain provisions to address unexpected events and disasters, such as the provisions discussed below, but many are not drafted to contemplate a scenario similar to the COVID-19 outbreak:

    • Force Majeure. Many real estate contracts contain a “force majeure” clause excusing a party’s non-performance when “acts of God” or other improbable events beyond a party’s control prevent a party from performing its obligations under the contract. Though force majeure clauses vary in scope and detail, rarely do they expressly list “epidemic” or “pandemic” as a force majeure event. Some force majeure provisions also provide that the delay may only be excused for a finite period of time, while others are narrowly drafted to apply only to events that make it “impossible” for a party to perform under the contract. Borrowers, developers and landlords, for example, will have to assess whether the force majeure provisions in their existing contracts will be triggered by anticipated COVID-19 impacts such as financial uncertainty affecting lenders, the impact of domestic and international travel restrictions on building material availability, the adverse effect of mandated quarantines on the availability of labor, and delays in obtaining necessary construction approvals caused by the closure of governmental agencies. On a prospective basis, parties that are required to perform should seek to negotiate broad force majeure clauses that are inclusive of delays due to a pandemic (and perhaps reference COVID-19 specifically), that provide flexibility for predictable delays, and that are not limited to a very brief time period.
    • Go-Dark Provisions. Many leases contain a “go-dark” provision that permits a tenant to discontinue its business operations for such time as the tenant continues to pay rent under the lease, but different parties to a real estate transaction will have different concerns to address with a go-dark provision:
      • A landlord, particularly in retail leases or with respect to major tenants, generally seeks to negotiate a covenant that requires a tenant to continuously operate its business during the term of its lease. Landlords may also negotiate a recapture right that permits the landlord to terminate the lease after the tenant has gone dark, without either party being in default.
      • A lender providing financing secured by a retail or single-tenant asset may provide that the failure of a tenant to continuously occupy its leased premises will trigger a cash management event under the loan documents.
      • Tenants and borrowers should negotiate for a flexible go-dark covenant so that a tenant discontinuing its operations due to COVID-19 concerns will not trigger a default under its lease or a cash management event under the loan documents; examples include (i) an extensive time period during which tenant may vacate the premises without triggering a recapture right or a cash management event (e.g., at least 180 days); (ii) carving out a temporary cessation of business activities due to force majeure; and/or (iii) for new leases, a “one-day covenant” that requires the tenant to be in occupancy for one day before a cessation of business activities will trigger a default under the lease.
    • Material Adverse Effect Provisions. The definition of material adverse effect (“MAE”) should be carefully considered. In real estate transactions, an MAE is generally defined as any condition that has, or can reasonably be expected to have, a material adverse effect on the property, business or financial makeup of a party:
      • In real estate-focused purchase and sale agreements and M&A transactions, it is typically a condition precedent to a party’s obligation to close that there be no MAE to the property, seller and/or target company, as applicable, as of the closing date.
      • Many real estate loan agreements provide for an immediate event of default if an MAE occurs, giving lenders the ability to exercise their acceleration rights. In a debt financing that provides for future advances, lenders will require that there be no MAE as a condition to making any advance.
      • Buyers looking to terminate a purchase transaction may argue that the effects of COVID-19 constitute an MAE.

    Although the economic and human costs of the coronavirus pandemic are great, it remains to be seen whether the impact of the COVID-19 pandemic will rise to the level of a MAE; parties negotiating contracts should be mindful of the ever-changing market conditions when negotiating this definition.

    • Compliance with Applicable Law. Congress, as well as state and city officials, are debating new legislation on a daily basis in an effort to slow the COVID-19 virus and, aside from any regulations that have been passed into law, the CDC is constantly releasing recommendations for maintaining the safety of the population.

      Depending on the applicable provisions of a lease, new legislation and/or CDC recommendations could trigger either a tenant’s covenant to comply with additional laws or a landlord’s covenant to provide additional services to its tenants, which could depend on a number of factors; for example, the obligations of a landlord of a net leased property are significantly different from those of a landlord of an office building with multiple tenants. The parties should also consider the service charge provision or adjusting the definition of “Operating Expenses” to determine whether a landlord can pass costs incurred in connection with its compliance of COVID-19 legislation to the tenant. (Many lease provisions contain a generic clause allowing the landlord to recover reasonable costs incurred in connection with commercially reasonable property management.) The parties to a lease negotiation should be conscious of the heightened costs and obligations attributable to COVID-19 regulations and be mindful to draft the lease accordingly.

    The impact of COVID-19 is continually evolving, but it is becoming clear that COVID-19 will change the way parties view many of the standard provisions of real estate contracts in the future. Much in the way the tragic events of 9/11 influenced the thinking of real estate professionals and introduced provisions into contracts protecting against the risks of terrorism, the provisions addressed in this Alert, among others, will likely be revised significantly in the coming months and years in response to the challenges posed by the COVID-19 outbreak.

    Authored by Julian M. Wise.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or the author.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Julian M. Wise

    Partner

    New York – 919 Third Avenue

    More insights

  • Activist Investing — COVID-19 and Shareholder Activism — The Impact

    Activist Investing — COVID-19 and Shareholder Activism — The Impact

    ARTICLE / CLIENT ALERT

    Activist Investing — COVID-19 and Shareholder Activism — The Impact

    March 17, 2020

    Read time: 5 min

    Key takeaways
    Overview

    No area is immune from the effects of the current COVID-19 crisis, including shareholder activism. For shareholders contemplating or already conducting an activist type campaign at a company, COVID-19 leads to logistical impediments and shifts in timing and strategy, but, importantly, also creates opportunities for savvy investors.

    Practical Impediments in Director Nominations

    At this time of the proxy season, many investors are submitting director nominations for election to the boards of directors of target companies. Currently, shareholders are experiencing practical impediments, mostly stemming from brokers and banks operating at reduced capacity. For example, some of the nation’s largest brokers are warning that transferring shares from a brokerage account into record name to be eligible to nominate a director may take a number of weeks. Alternative processes that we have used in the past to avoid these problems are also expected to take at least as long. (For context, these logistical steps ordinarily take 2 to 3 business days in regular markets.)

    In addition to share ownership issues, director nominees themselves are often working remotely and requiring more time to complete relevant documentation. These delays can be further compounded, where nominees must secure approvals from other companies or their employers in order to be a nominee.

    The cumulative lesson of this is clear: shareholders contemplating nominations should start early and initiate the process, even if they are not yet certain about their plans in order to preserve their rights and optionality in the event a campaign proves desirable.

    Impact of SEC Operating Slowdown

    Even after nominations, the proxy filing process may also be affected, as the strain on resources at the SEC may affect the speed and ease of being cleared to proceed with the campaign.

    Normally in contested elections, the SEC comments extensively on all proxy materials, including those prior to commencing solicitation, in order to ensure that shareholders can rely on truthful information in making their voting decisions. Both sides spend significant time working to clear the SEC process quickly so they can solicit votes for their cause.

    If comments from the SEC during the COVID-19 crisis end up being less rigorous, parties need to be prepared for more aggressive rhetoric and escalation in the tone of campaigns, which could force fact-checking into the public space.

    Activists should be particularly vigilant in seeking substantiation from a defending company that may try to take advantage of a less rigorous SEC review and should be prepared to issue frequent press releases and letters to shareholders setting the record straight.

    Active Solicitations May Face Challenges Getting Attention

    During a campaign, an activist frequently looks to focus shareholder attention on the identified company issues and propose solutions to improve the company.

    COVID-19 has spurred historic levels of market volatility and many market participants are focused on current portfolio valuations and trying to anticipate how future market behavior will affect their investments. This raises challenges in gaining the attention for an activist thesis (particularly a more long-term proposal), as well atypical challenges in convincing investors that suggested changes will deliver results.

    Activist Opportunities Abound

    Of course, market volatility cuts both ways. This crisis may result in widespread delays in annual financial reporting by public companies and shifts in annual meeting dates, all of which could provide activists extra time to build their theses and present them to shareholders. A simple, easy-to-understand platform that can resonate with worn out and nervous investors may play best.

    Increased settlement may be another likely side effect of COVID-19-provoked market volatility. With the outcome of contests more uncertain, sides may find added incentive to come to terms rather than take the risk of going to a vote.

    Attractive Prices for High-Conviction Positions

    The market slump offers a welcome opportunity to economically increase holdings in companies where activists have a high-conviction thesis. Activists have recently continued to attract significant capital and many are sitting on large war chests, frequently with long duration lockups. This should allow them to weather short-term market turmoil.

    Once the dust settles and market valuations reflect reality, underperforming companies will be exposed, creating major opportunities for activism. In the short term, investors should position themselves opportunistically to take advantage of this future potential.

    Authored by Eleazer Klein and Aneliya S. Crawford.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Ele Klein

    Partner

    New York – 919 Third Avenue

    More insights

  • CLO Guidance — The Impact of COVID-19 — Considerations for Managers of Collateralized Loan Obligations

    CLO Guidance — The Impact of COVID-19 — Considerations for Managers of Collateralized Loan Obligations

    ARTICLE / CLIENT ALERT

    CLO Guidance — The Impact of COVID-19 — Considerations for Managers of Collateralized Loan Obligations

    March 17, 2020

    Read time: 4 min

    Key takeaways
    Overview

    The recent worldwide outbreak of coronavirus disease 2019 (“COVID-19”) has resulted in extraordinary actions, including quarantines and “social distancing,” which is currently disrupting economic activity in the United States and globally.

    This, coupled with a disruption in the energy industry due to a severe drop in oil prices resulting from a lack of agreement on drilling output limits by certain OPEC nations, is having a negative effect on certain industries.

    On Sunday, March 15, 2020, the Open Market Committee of the Federal Reserve Bank reduced the target range for the federal funds rate to 0.00% — 0.25%, and the U.S. Congress is currently considering emergency legislation to support the economy throughout the crisis. Actions by federal, state and local governments to mitigate the impact of the coronavirus, as well as continued market volatility arising from the spread of coronavirus, are likely to affect collateralized loan obligations (“CLOs”) and their underlying assets. CLO managers should consider the effects this will have on their CLO transactions and should note the following:

    1. CLOs usually carry their collateral obligations (other than collateral obligations purchased at a discount) at par value for purposes of overcollateralization tests; however defaulted collateral obligations are typically counted at market value for overcollateralization tests, and collateral obligations whose ratings are “CCC+” or below (to the extent not treated as defaulted obligations) are also typically adjusted for purposes of the overcollateralization tests.
    2. For CLOs purchasing collateral obligations at deeply discounted prices (below certain threshold prices, depending on the ratings of the obligations) at this time, it is important to recall that these collateral obligations typically will be carried at their purchase price for purposes of the overcollateralization tests.
    3. Should loan prices continue to decline, CLO managers should review their ability to swap discounted collateral obligations with the sale proceeds of a collateral obligation without having to treat the new loan as a discount collateral obligation. In addition, CLO managers should take note of their minimum purchase price criteria.
    4. If CLO loan portfolios deteriorate (whether as a result of price declines, ratings downgrades on individual loans, or a general weakening of obligors’ financial strength) and rating agencies begin to downgrade CLO notes, the ability to trade loans may be suspended if a “restricted trading period” goes into effect under a CLO’s indenture.
    5. CLO managers should review their CLO indentures to determine their ability to agree to amendments, restructurings and workouts in anticipation of loan obligors looking to take certain actions.
    6. Engagement letters for CLOs usually have “no material adverse effect” conditions that are broadly written and expressly include the absence of adverse market conditions, which if not satisfied in the discretion of the CLO arranger, entitle the arranger to determine not to proceed with the CLO.
    7. Arrangers and other banks that provide warehouse credit facilities (whether in anticipation of a CLO or as permanent financing) will usually retain full discretion to approve assets to be acquired under the warehouse facility. During adverse market conditions, the bank could use this discretion to cease approving assets.
    8. CLO managers that have warehouse credit facilities with market value default triggers or funding conditions might want to consider their options if a trigger is hit (e.g., make additional equity contributions, liquidate certain assets, or prepay the facility).

    There will be economic challenges posed by the coronavirus and the global response to it, and CLOs are likely to feel the effects. Schulte Roth & Zabel will continue to provide updates as further developments become known.

    Authored by Phillip J. Azzollini, Daniel V. Oshinsky, Craig Stein, James V. Williams, III and Vera Quagliato.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Phillip J. Azzollini

    Partner

    New York – 919 Third Avenue

    Daniel V. Oshinsky

    Partner

    New York – 919 Third Avenue

    Craig Stein

    Partner

    New York – 919 Third Avenue

    Vera Quagliato

    Partner

    New York – 919 Third Avenue

    More insights

  • Business Interruption and Related Insurance for Losses from COVID-19

    Business Interruption and Related Insurance for Losses from COVID-19

    ARTICLE / CLIENT ALERT

    Business Interruption and Related Insurance for Losses from COVID-19

    March 17, 2020

    Read time: 5 min

    Key takeaways
    Overview

    On March 10, 2020, the New York State Department of Financial Services (“NYDFS”) instructed all authorized property/casualty insurers to “explain to policyholders the benefits under their policies and the protections provided in connection with COVID-19.” The instruction requires insurers to provide specific information concerning business interruption, contingent business interruption, civil authority and supply chain coverage to their policyholders.

    Insurers are Required to Explain Coverage for Business Interruption Losses

    By March 18, 2020, each insurer is required to provide to each of its policyholders and the NYDFS a “clear and concise explanation of benefits that is suitable for policyholder review,” including, without limitation, the following questions and requests:

    • “What type of commercial property insurance or otherwise related insurance policy does the insured hold?
    • Does the insured’s policy provide ‘business interruption’ coverage? If so, provide the ‘covered perils’ under such policy. Please also indicate whether the policy contains a requirement for ‘physical damage or loss’ and explain whether contamination related to a pandemic may constitute ‘physical damage or loss.’ Please describe what type of damage or loss is sufficient for coverage under the policy.
    • Does the insured’s policy provide ‘civil authority’ coverage? If so, please describe what type of damage or loss is sufficient for coverage under the policy. Please also describe any relevant limitations under the policy. Please explain whether a civil authority prohibiting or impairing the policyholder’s access to its covered property in connection with COVID-19 is sufficient for coverage under the policy.
    • Does the insured’s policy provide ‘contingent business interruption’ coverage? If so, please describe what type of damage or loss is sufficient for coverage under the policy. Please provide the ‘covered perils’ under such policy. Please also indicate whether the policy contains a requirement for ‘physical damage or loss’ and explain whether contamination related to a pandemic may constitute ‘physical damage or loss.
    • Does the insured’s policy provide ‘supply chain’ coverage? If so, is such coverage limited to named products or services from a named supplier or company? Please also indicate whether the policy contains a requirement for ‘physical damage or loss’ and explain whether contamination related to a pandemic may constitute ‘physical damage or loss.’
    • For each instance of coverage described above, please provide the applicable waiting period under the insured’s policy. Please also indicate the amount of time coverage remains in effect once becomes active for a given incident.”

    Key Business Interruption Coverage Issues

    Whether or not business interruption or contingent business interruption coverage will respond to COVID-19 claims will depend on the terms of each individual policy. Many business interruption policies, for example, specifically require physical damage or loss while other policies may exclude losses arising out of infectious diseases. (Certain states, including New Jersey, are considering bills to remove the infectious disease exclusions in the wake of COVID-19.)

    Directors and Officers (“D&O”) Coverage

    COVID-19 business losses will likely result in claims against directors and officers alleging wrongful acts or failures to act that are alleged to have resulted in business losses. These claims could include allegations that the business failed to develop and timely implement contingency or business continuity plans or failed to adequately disclose risks inherent to the business from disease, supply chain disruptions or governmental actions. D&O policy claims will have to overcome bodily injury exclusions typical to those policies, however, such exclusions may not apply where loss is wholly economic.

    General Liability (“GL”) and Workers’ Compensation

    For businesses that serve customers who become infected by the coronavirus, third party GL insurance should be available where a claimant can show that the infection was the result of their interaction with the business and the business failed to exercise reasonable care. Employees may also be able to assert bodily injury claims which should trigger coverage under their employers’ workers’ compensation policies. In some cases, insurers may argue that the infection did not occur during the course of employment and that the coronavirus was not an occupational disease as distinguished from a disease to which the general public is ordinarily exposed.

    Other Coverage

    Policyholders should also be mindful of potential coverage under specialized insurance policies including Key Man, Political Risk and Event Cancellation, as well as Pandemic Disease Insurance policies developed in response to the Ebola and SARS epidemics.

    Authored by Howard B. Epstein and Theodore A. Keyes.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Howard B. Epstein

    Of Counsel

    New York – 919 Third Avenue

    Theodore A. Keyes

    Partner

    New York – 919 Third Avenue

    More insights

  • SEC Staff Issues COVID-19 Guidance Relating to Annual Shareholder Meetings and Compliance with Federal Proxy Rules

    SEC Staff Issues COVID-19 Guidance Relating to Annual Shareholder Meetings and Compliance with Federal Proxy Rules

    ARTICLE / CLIENT ALERT

    SEC Staff Issues COVID-19 Guidance Relating to Annual Shareholder Meetings and Compliance with Federal Proxy Rules

    March 17, 2020

    Read time: 8 min

    Key takeaways
    Overview

    In view of the “health, transportation, and other logistical issues raised by the spread of the coronavirus,” the respective staffs of the Division of Corporation Finance and Division of Investment Management of the Securities and Exchange Commission (“Commission”) have jointly issued guidance addressing a number of issues pertaining to annual shareholder meetings of public companies, including registered investment companies and business development companies (each, an “Issuer”), as well as to related federal proxy rules (“Staff Statement”).[1] The guidance provided reflects a continued focus by the staff on the impact that the coronavirus may have on in-person meetings generally, both at the board and shareholder level.[2] In particular, the Staff Statement addresses:

    • Filing and disclosure requirements relating to any change in the date, time or location of an annual shareholder meeting subsequent to the mailing of an Issuer’s definitive proxy materials;
    • The use of “virtual” shareholder meetings by Issuers; and
    • Presentation obligations for proponents of shareholder proposals submitted to Issuers pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (“Exchange Act”).

    The Staff Statement also encourages “all parties and intermediaries involved in the proxy voting process — including broker-dealers, transfer agents, and proxy service providers — to be flexible and work collaboratively with one another” in view of the disruptions that will likely continue to occur as a result of the coronavirus.[3]

    Changes in the Date, Time or Location of an Annual Shareholder Meeting

    As a number of Issuers have already filed their definitive proxy materials with the Commission and commenced delivery to their shareholders, the Staff Statement clarifies that these Issuers may change the date, time or location of their previously announced annual shareholder meeting, without formally amending their proxy materials or delivering an amendment to their shareholders, as long as such Issuers:

    • Issue a press release announcing the change;
    • File the announcement with the Commission as definitive additional soliciting material; and
    • Take all reasonable steps to inform other intermediaries in the proxy process (such as proxy service providers), other relevant market participants and the national securities exchange where an Issuer’s securities are listed, if any, of the change.

    The Staff Statement further clarifies that Issuers should take such steps promptly after making any decision to change the date, time or location of an annual shareholder meeting, and do so “sufficiently in advance of the meeting so the market is alerted to the change in a timely manner.”[4] The staff also encourages Issuers who have not yet mailed their definitive proxy materials to consider including disclosures regarding the possibility that the date, time or location of an Issuer’s annual shareholder meeting may be changed from that included in its proxy materials delivered to shareholders, depending on an Issuer’s particular circumstances and the reasonable likelihood of such a change.

    The nature of the guidance provided by the staff appears focused on balancing the need to streamline the process for Issuers to change the date, time or location of their annual shareholder meeting in view of the impact of the coronavirus with a desire to ensure that no shareholders are disenfranchised as a result of such change. As a result, Issuers should be mindful about ensuring adequate disclosure and dissemination of any change in the date, time or location of their annual shareholder meeting subsequent to mailing of their definitive proxy materials, even if no amended definitive proxy materials are mailed to shareholders. In addition, Issuers who have not yet mailed definitive proxy materials may wish to include language regarding the possibility of a change, including to a “virtual” shareholder meeting format, to preserve optionality in the event current plans for an in-person shareholder meeting no longer remain viable.

    “Virtual” Shareholder Meetings

    The Staff Statement also addresses the use of “virtual” shareholder meetings, held using the internet or other electronic means in lieu of an in-person meeting, and “hybrid” shareholder meetings, which involve an in-person meeting that also permits shareholder participation through electronic means. In particular, the Staff Statement emphasizes the need for Issuers that intend to utilize a “virtual” or “hybrid” shareholder meeting structure to:

    • Provide adequate notice of the meeting structure to their shareholders, intermediaries in the proxy process and other relevant market participants; and
    • Ensure that the logistical details of the meeting, including how shareholders may remotely access, participate in, and vote at the meeting, have been adequately disclosed.

    Notably, the guidance on “virtual” shareholder meetings remains focused on ensuring that shareholders continue to have the same access as they would with a traditional in-person meeting. To that end, the Staff Statement clarifies that the detailed information with respect to any “virtual” or “hybrid” shareholder meeting structure should be included in an Issuer’s definitive proxy materials and other soliciting materials. However, to the extent an Issuer that has previously filed and mailed its definitive proxy materials desires to switch to a “virtual” or “hybrid” shareholder meeting structure, it may do so utilizing the same procedures as described above for a change in the date, time or location of an Issuer’s annual shareholder meeting.

    Issuers contemplating a switch to a “virtual” or “hybrid” shareholder meeting format should first confirm that applicable state law permits them to forgo a traditional in-person meeting structure. In addition, in view of the guidance provided in the Staff Statement, Issuers who contemplate utilizing a “virtual” or “hybrid” shareholder meeting format should ensure that they include sufficient information in their definitive proxy materials regarding the process for shareholders to attend, participate in and vote at such shareholder meeting. Issuers considering holding a “virtual” or “hybrid” meeting must also assess the feasibility of doing so from a technological and logistical standpoint, and should work closely with proxy service providers to help ensure a seamless meeting experience for shareholders. Given the fast-moving developments relating to the coronavirus outbreak, even Issuers who do not currently plan to utilize a “virtual” or “hybrid” shareholder meeting framework may wish to include language regarding the possibility of such a change in their definitive proxy materials, to the extent holding a traditional in-person shareholder meeting becomes untenable.

    Presentation of Shareholder Proposals at Annual Shareholder Meetings

    The Staff Statement also addresses the requirement set forth in Rule 14a-8(h) under the Exchange Act that a shareholder proponent, or a representative thereof, appear and present the proponent’s proposal at an Issuer’s annual shareholder meeting. Specifically, in view of the difficulties proponents may have attending an Issuer’s annual shareholder meeting in view of the coronavirus outbreak, the Staff Statement encourages Issuers to allow proponents to present their proposals through alternative means, including telephonically, during the 2020 proxy season, to the extent permitted under applicable state law.

    Notably, however, the Staff Statement does not expressly require Issuers to make such accommodations for shareholder proponents, which may make it more difficult for potential proponents to meet the requirements of Rule 14a-8(h) in the event travel restrictions or other factors arising from the coronavirus outbreak prevent them from attending an Issuer’s in-person annual shareholder meeting. To that end, the staff indicates that it will consider the inability of a shareholder proponent to travel or other hardships related to the coronavirus to constitute “good cause” under Rule 14a-8(h), should an Issuer seek to assert Rule 14a-8(h)(3) as a basis for excluding a proposal submitted by such shareholder proponent for any shareholder meetings held during the following two calendar years.[5]

    In view of the impact of the coronavirus generally, Issuers may wish to provide the type of accommodations suggested by the staff to shareholder proponents to avoid even the appearance of taking advantage of the current circumstances, particularly to the extent a shareholder proponent’s proposal is merely precatory in nature. In addition, shareholder proponents who have submitted proposals under Rule 14a-8 should seek clarification from Issuers regarding what accommodations, if any, they intend to provide to shareholder proponents with proposals pending at upcoming annual shareholder meetings.

    Authored by Eleazer Klein.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] Staff Guidance for Conducting Annual Meetings in Light of COVID-19 Concerns (March 15, 2020), https://www.sec.gov/ocr/staff-guidance-conducting-annual-meetings-light-covid-19-concerns (“Staff Guidance for Conducting Annual Meetings”).

    [2] See Division of Investment Management Staff Statement on Fund Board Meetings and Unforeseen or Emergency Circumstances Related to Coronavirus Disease 2019 (COVID-19) (March 4, 2020), https://www.sec.gov/investment/staff-statement-im-covid-19

    [3] Staff Guidance for Conducting Annual Meetings.

    [4] Id.

    [5] Under Rule 14a-8(h)(3), if a shareholder proponent, or a representative thereof, fails to appear and present the proponent’s shareholder proposal at an Issuer’s annual shareholder meeting, the Issuer may exclude any proposals that proponent may submit during the following two calendar year periods.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Ele Klein

    Partner

    New York – 919 Third Avenue

    More insights

  • Employment Law — Section 409A Deadlines — Considerations for Employers Impacted by COVID-19

    Employment Law — Section 409A Deadlines — Considerations for Employers Impacted by COVID-19

    ARTICLE / CLIENT ALERT

    Employment Law — Section 409A Deadlines — Considerations for Employers Impacted by COVID-19

    March 17, 2020

    Read time: 3 min

    Key takeaways
    Overview

    In light of the disruptions caused by the COVID-19 pandemic, employers that maintain bonus arrangements are reminded of certain deadlines imposed under Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”).

    First, bonus arrangements, whether under bonus programs or individual agreements with employees, that are designed to be exempt from the requirements of Section 409A might specifically require payment by March 15, 2020 to avoid the more onerous requirements of Section 409A. In general, an employee must be paid compensation designed to qualify as a “short term deferral” within 2-1/2 months of the year in which the employee became vested in the compensation (i.e., met all the requirements to be paid and is not required to continue employment through the payment date). Fortunately, an employer who might have missed this deadline due to the COVID-19 pandemic may be eligible to rely on relief under Section 409A. Payments that should have been made by an employer by March 15 may still qualify as exempt from Section 409A if the employer can establish that it was administratively impracticable to make the payment on time because of the unforeseeable events arising from the pandemic, provided that the employer actually makes the payment as soon as administratively practicable after March 15.

    Employers should also consider a second Section 409A deadline coming soon that affects deferred compensation arrangements that permit employees to defer “performance-based compensation.” Those arrangements rely on a special rule under Section 409A that allows employees to make deferral elections with respect to “performance-based compensation” up to six months before the end of the applicable performance period — otherwise, section 409A generally requires such elections to be made before the start of the calendar year. To qualify as performance-based compensation for this exception, one primary requirement is that the performance criteria must be established in writing no later than 90 days after the commencement of the performance period — in the case of calendar year bonuses, that date is March 30, 2020. There is no exception under Section 409A to this deadline. As a result, despite the current economic uncertainty, employers with such deferral arrangements must ensure that the performance criteria be established by March 30.

    Authored by Ian L. Levin and Adam B. Gartner.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Ian L. Levin

    Partner

    New York – 919 Third Avenue

    Adam B. Gartner

    Special Counsel

    New York – 919 Third Avenue

    More insights

  • CMS Final Rule Aims to Advance Interoperability, Exchange of Clinical and Plan Information

    CMS Final Rule Aims to Advance Interoperability, Exchange of Clinical and Plan Information

    CLIENT ALERT / INFORMATION BLOCKING / INTEROPERABILITY

    CMS Final Rule Aims to Advance Interoperability, Exchange of Clinical and Plan Information

    March 16, 2020

    Read time: 10 min

    Key takeaways
    Overview

    The Centers for Medicare & Medicaid Services (CMS) published its highly anticipated final rule aimed at enhancing interoperability and increasing patient access to health information. CMS’s final rule will require hospitals and payors to make significant investments in their health information technology to comply with the new requirements, effective six months following publication of the final rule in the Federal Register for hospitals, and January 1, 2021, for payors. In this On the Subject, we analyze the final rule requirements, which include a new requirement that CMS-regulated payors offer application programming interfaces, and a new Medicare condition of participation that requires hospitals with electronic health record systems to send electronic patient event notifications to communicate transitions of care.

    In depth

    On March 9, 2020, the US Department of Health and Human Services (HHS) Centers for Medicare & Medicaid Services (CMS) announced a final rule aimed at enhancing interoperability and increasing patient access to health information. The final rule requires CMS-regulated payors and agencies (Covered Plans and Agencies) to implement application programming interfaces (APIs) that allow patient information to be shared more readily between patients, healthcare providers, payors and third-party applications selected by patients. APIs could improve patients’ ability to gain access to their health information and share key medical history information with other providers and payors. Notably, however, HIPAA does not apply to many third-party applications that patients would use to access their data, raising stakeholder concerns about the privacy and security of information shared through APIs.

    The final rule also requires hospitals that have adopted electronic health record systems to engage in electronic event reporting of patient admissions, discharges and transfers to patients’ primary care practitioners as a condition of participation (CoP) in the Medicare program. Hospitals and payors may need to make significant investments in health information technology (IT) to comply with the new requirements, which go into effect six months following publication of the final rule for hospitals, and on January 1, 2021, for payors.

    This highly anticipated final rule has already garnered responses from key industry players, including America’s Health Insurance Plans, the nationwide association of health insurers, which stated that it shares HHS’s vision for expanded consumer data access but “remain[s] gravely concerned that patient privacy will still be at risk when health care information is transferred outside the protections of federal patient privacy laws.” The association cautioned that “any new rules must ensure we protect patient privacy, reduce health care costs, and get personalized information into the hands of patients.”

    On the same day that CMS released the final rule, the HHS Office of the National Coordinator of Health IT (ONC) released a final rule implementing the information blocking provisions of the 21st Century Cures Act and updates to ONC’s health IT certification program. A separate On the Subject about the ONC final rule is forthcoming.

    Read on for a summary of the key requirements and implications of the CMS final rule, and recommended next steps for payors and hospitals. For a review of our past coverage on these rules, please visit our Regulatory Sprint to Coordinated Care Resource Center.

    Application Programming Interfaces

    Under the final rule, Covered Plans and Agencies—which include Medicare Advantage (MA) plans, Medicaid state agencies, Medicaid managed care plans, Children’s Health Insurance Program (CHIP) agencies, CHIP Managed Care entities, and issuers of qualified health plans in federally facilitated exchanges, except for stand-alone dental plans—must adopt and implement an “openly published” API that permits third-party software applications to retrieve, at the direction of the patient or health plan member, a significant amount of clinical and payment information. The API technology must meet health IT standards established by ONC. Covered Plans and Agencies must comply by January 1, 2021.

    The Covered Plan or Agency must make the following information available through the API:

    • Data concerning adjudicated claims and encounter data, including claims data for payment decisions that may be appealed, were appealed, or are in the process of appeal, and provider remittances and enrollee cost-sharing pertaining to such claims
    • Clinical data, including laboratory results, if the Covered Plan or Agency manages such data.

    The Covered Plans and Agencies must make this information available no later than one business day after a claim is adjudicated or the Covered Plan or Agency receives the data.

    For MA plans, Medicaid and CHIP fee-for-service programs, Medicaid managed care plans and CHIP managed care entities, the API must also allow access to a provider directory of the payor’s network of contracted providers, including names, addresses, phone numbers and specialties, updated no later than 30 calendar days after the payor receives the information or an update.

    For MA organizations that offer Part D plans, the API must allow the third-party application to retrieve:

    • Standardized data concerning adjudicated claims for covered Part D drugs, including remittances and enrollee cost-sharing, no later than one business day after a claim is adjudicated
    • Pharmacy directory data, including the number, mix and addresses of network pharmacies
    • Formulary data that includes covered Part D drugs and any tiered formulary structure or utilization management procedure that pertains to those drugs.

    While the open API initiative in the final rule specifically applies to Covered Plans and Agencies, CMS also expressed the hope that other stakeholders, such as state-operated exchanges and private payors, will adopt similar requirements for access to information and interoperability so that even more patients can broadly access their health information and better manage care.

    Payor-to-Payor Data Exchange

    In addition to proposing payor-to-patient exchanges through APIs, CMS also finalized its proposal to require MA plans, Medicaid managed care plans, CHIP managed care entities and qualified health plan issuers on the federally facilitated exchanges to forward patient information maintained within the ONC-identified US Core Data Set for Interoperability to other payors designated by the requesting patient for up to five years after the patient has disenrolled from the plan (with the approval and direction of the patient). CMS anticipates that payors will leverage the API they put in place to comply with patient access requirements to additionally provide other payors access to the same data. CMS allows payors to use other methods of data exchange to accomplish this requirement, however. Covered Plans and Agencies must comply with the payor-to-payor exchange requirement by January 1, 2022.

    Notably, CMS elected to not finalize its proposal to require Covered Plans and Agencies to participate in trusted health information exchange networks. CMS noted that although some commenters showed support for the proposal, other commenters noted the need for a mature Trusted Exchange Framework and Common Agreement (TEFCA), a set of policies and procedures for interoperable exchange, to be put in place first. ONC published a second draft TEFCA on April 19, 2019, but has not yet finalized it.

    Hospital Condition of Participation

    CMS finalized its proposal to adopt a Medicare hospital CoP that requires hospitals, psychiatric hospitals and critical access hospitals (CAHs) that have electronic event notification capabilities to send electronic notifications upon a patient’s admission, discharge or transfer to or from the hospital’s emergency department or inpatient service department. The CoP becomes effective six months after the final rule’s publication in the Federal Register.

    CMS modified the CoP slightly from the proposed rule. The final CoP does not require hospitals to include diagnosis information within the notification. Instead, the notification must include at a minimum the patient’s name, treating practitioner name and sending institution name. The CoP does not require hospitals to send notifications to all providers that have an “established care relationship” with the patient, but only to the patient’s established primary care practitioner or other practitioner or practice group identified by the patient as primarily responsible for the patient’s care.

    CMS stated that electronic patient event notifications, or automated electronic communications from discharging providers to another facility, could improve care coordination and potentially reduce readmissions by making a receiving provider aware of the care the patient has received elsewhere. However, this CoP creates a new set of requirements on top of existing Promoting Interoperability measures that CMS adopted to incentivize the use of health IT to improve care. Hospitals must already spend significant resources to achieve the Promoting Interoperability measures, and the new CoP requirement will likely increase hospitals’ overall compliance burden with respect to health IT implementation.

    Information Blocking and Public Reporting

    The final rule discourages clinicians from engaging in the practice of information blocking by requiring the public display, via an indicator on the Physician Compare website, of physicians and other clinicians who fail to attest as part of the CMS Merit-based Incentive Payment System (MIPS) program that they:

    • Did not knowingly and willfully take action to limit or restrict the compatibility or interoperability of certified health IT
    • Implemented technologies and practices to ensure that their certified health IT is connected and compliant with applicable law
    • Responded in good faith and in a timely manner to requests to retrieve or exchange electronic health information.

    Clinicians who fail to attest “yes” to the above statements would receive a potential reduction of Medicare reimbursement under MIPS, in addition to the negative indicator on the CMS Physician Compare website, which is available to patients who are seeking to compare Medicare-participating physicians and other clinicians.

    CMS also requires eligible hospitals and CAHs to make “yes/no” attestations concerning their use of certified health IT in order to participate in the CMS Promoting Interoperability program. A hospital or CAH’s failure to attest “yes” will result in a negative indicator on a future CMS website that will display hospitals’ attestations under the Medicare Promoting Interoperability program.

    CMS included these reporting requirements in the final rule to discourage hospitals and clinicians from engaging in information blocking. CMS expects to post the information for both clinicians and hospitals in late 2020.

    Recommended Next Steps

    The final rule will have a significant impact on Covered Plans and Agencies and hospitals. These entities should consider taking several practical steps in response to the final rule.

    Recommendations for Covered Plans and Agencies

    Covered Plans and Agencies should consider the following next steps in response to the final rule:

    • Assess the technological capabilities of IT systems and quickly make any necessary adjustments to offer an API that is consistent with ONC standards
    • Develop user guides or other resources that explain how a plan member or patient may obtain data through the API and protect their privacy by only selecting reputable third-party applications
    • Work with other Covered Plans and Agencies to develop technical mechanisms and policy frameworks for connecting and sharing data in accordance with the payor-to-payor exchange requirement, which becomes effective in 2022.

    Recommendations for Hospitals and CAHs

    Given the aggressive timelines in the final rule, hospitals will soon need to assess the capabilities of existing IT systems and their readiness to send electronic notifications as required by the new CoP. Even with necessary systems in place, hospitals should review their intake and discharge workflows to ensure that they are consistently identifying the practitioner primarily responsible for patients admitted to the emergency and inpatient departments. To the extent that hospitals are not consistently capturing this information, they should consider revising their policies, procedures and training to emphasize the importance of obtaining the information, and should set up event notifications to the identified individual or group practice.

    If you would like assistance in complying with any of the new requirements, please contact one of the authors or your regular McDermott lawyer.


    Our experienced team, which includes several attorneys who previously worked at the US Department of Health & Human Services (HHS), has advised many clients on the potential impact of the HHS proposed rules on their businesses and has analyzed the final rules. We will host a series of webinars to discuss the final rules. Details are below and you may register by clicking here.

    • March 23, 2020: ONC Final Information Blocking Rule
    • March 26, 2020: CMS Interoperability Rule
    • March 31, 2020: Navigating the New ONC Requirements for APIs
    Authors

    James A. Cannatti III

    Partner

    Washington, DC

    Daniel F. Gottlieb

    Partner

    Chicago

    More insights

  • Cybersecurity — Homeland Security Warns of Coronavirus-Related Cybersecurity Risks — Considerations for Private Fund Managers

    Cybersecurity — Homeland Security Warns of Coronavirus-Related Cybersecurity Risks — Considerations for Private Fund Managers

    ARTICLE / CLIENT ALERT

    Cybersecurity — Homeland Security Warns of Coronavirus-Related Cybersecurity Risks — Considerations for Private Fund Managers

    March 16, 2020

    Read time: 10 min

    Key takeaways
    Overview

    On March 5, 2020, SRZ hosted a webinar on coronavirus preparedness during which we addressed certain cybersecurity and data risks that arise from working in a distributed workforce environment, as well as risks from cyber criminals exploiting the curiosity and fear surrounding the coronavirus outbreak.[1] On March 13, 2020, the U.S. Department of Homeland Security’s Cybersecurity and Infrastructure Security Agency (“CISA”) issued a warning about these issues and encouraged organizations that move to a remote working environment “to adopt a heightened state of cybersecurity.”

    CISA Guidance. The March 13, 2020 CISA Alert lists a number of cybersecurity risks associated with telework, such as increased reliance on virtual private networks (“VPNs”) that may not be updated with the latest security updates and patches or that do not utilize multi-factor authentication (“MFA”) for remote access. CISA’s Alert also recommends specific steps businesses can take to mitigate these increased risks:

    • Update VPNs, network infrastructure devices and devices being used to remote into work environments with the latest software patches and security configurations;
    • Alert employees to an expected increase in phishing attempts;
    • Ensure IT security personnel are prepared to ramp up remote access cybersecurity tasks, including log review, attack detection and incident response and recovery and document these tasks in the configuration management policy;
    • Implement MFA on all VPN connections to increase security (or if MFA is not implemented, require teleworkers to use stronger passwords);
    • Ensure IT security personnel test VPN limitations to prepare for mass usage and, if possible, implement modifications — such as rate limiting — to prioritize users that will require higher bandwidths; and
    • Contact CISA to report incidents, phishing, malware and other cybersecurity concerns.

    CISA and other government agencies have been warning for several weeks about the risks posed by cyber criminals and other scammers exploiting the pandemic.[2] While cybersecurity risks may be exacerbated in a telework environment, remember that they will continue to be heightened in traditional work settings and are not limited to the United States.

    Implications for Private Fund Managers. The CISA Alert is not directed at any particular industry or sector, but it has obvious implications for private fund managers. At this point, most managers have tested their disaster recovery/business continuity plans and many have already shifted to a partial or complete “work-from-home” footing. However, the CISA Alert serves as a reminder that, in some ways, the cybersecurity risks, and need for vigilance, are just starting.

    In particular, managers need to be reminding employees of the dangers posed by phishing emails, which are becoming more sophisticated and difficult to spot. Phishing attempts already reported during this crises include:

    • Communications that look like they were sent by the World Health Organization[3] or another health or governmental organization;
    • Fake purchase orders for face masks or other supplies;
    • False “remote workplace testing” emails that request login or other authentication information; and
    • Requests for donations that spoof legitimate relief organizations.

    To succeed, a phishing attack only needs to convince one employee to click a link, open an attachment, or provide authentication information, which could compromise a manager’s security or unleash malware that could render some or all of a company’s systems inaccessible for an extended period of time. These threats pose significant harm and business interruptions under the best of circumstances but can be even more debilitating and difficult to address for offices that have moved partially or fully to remote work and reduced on-site IT monitoring and support.

    Because employees are a major point of vulnerability, email alerts, trainings (which can be conducted via webinar or teleconference) and phishing tests (i.e., sending phishing simulation emails) can go a long way in mitigating the risks. Many managers have existing information security training programs and materials that can be leveraged for this purpose.

    Additionally, while many managers already have a team and response plan in place for cyber incidents, adjustments should be considered to ensure the business is well-positioned to address cyber incidents in the current environment.

    As before, should a cybersecurity incident occur, managers are reminded to consider any required notices to personnel or other affected individuals, as well as governmental authorities. For example, if investor information is accessed or extracted from the system, it could trigger reporting obligations under data breach notifications laws.

    Authored by Brian T. Daly, Marc E. Elovitz, Edward H. Sadtler and Kelly Koscuiszka.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] Please contact events@srz.com if you would like the materials from that webinar.

    [2] For example, CISA issued a March 6, 2020 Alert regarding cyber scams related to the coronavirus; the Federal Trade Commission issued a Feb. 10, 2020 Alert related to fake websites, emails and fundraising efforts related to the coronavirus, and the Securities and Exchange Commission’s Office of Investor Education and Advocacy issued a Feb. 4, 2020 investor Alert warning investors about investment frauds involving claims that a company’s products or services will be used to help stop the coronavirus outbreak.

    [3] The World Health Organization maintains a cybersecurity page with tips to assist organizations in validating communications and a link for reporting scams.  


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Marc E. Elovitz

    Partner

    New York – 919 Third Avenue

    Kelly Koscuiszka

    Partner

    New York – 919 Third Avenue

    More insights